natgillin/translations-raw huggingface dataset:
The antisense oligonucleotide of claim 1, wherein the oligonucleotide is chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the antisense oligonucleotide. 
Antisens oligonukleotid u skladu sa zahtjevom 1, naznačen time što navedeni antisens oligonukleotid je kemijski vezan na jedan ili više ostataka ili konjugata koji poboljšavaju aktivnost, raspodjelu po stanici ili unos u stanicu antisens oligonukleotida.
For sanitation, the column was flushed with at least 6 BV of 1M NaOH, the flow stopped for 1 hour, and the column then rinsed with at least 6 BV of purified water. 
Za sterilizaciju, kolona je bila oprana s najmanje 6 BV IM NaOH, protok je zaustavljen nakon 1 sata, a kolona je tada oprana s najmanje 6 BV pročišćene vode.
Subsequently, once the stirred suspension had cooled, H2O (1 L) was added prior to being extracted 4× with EtOAc. 
Zatim, nakon što se miješana suspenzija ohladila, dodana je H2O (1L) prije ekstrahiranja 4x sa EtOAc.
The pharmaceutical composition of claim 10 for use in a method of treating a proliferative disorder. 
Sol namijenjena upotrebi u skladu s patentnim zahtjevom 11, naznačena time što je proliferativni poremećaj Tak.
A composition for use according to any preceding claim wherein the degarelix is for administration at an initial dose of 160 to 320 mg; and at a maintenance dose of 60 to 160 mg, once every 20 to 36 days thereafter. 
Sastav za upotrebu prema patentnom zahtjevu 1 ili 2 za primjenu u inicijalnoj dozi degareliks od 160 do 320 mg; i održavajućoj dozi od 60 do 160 mg, jednom svakih 20 do 36 dana nakon toga.
The crystalline Form I of claim 1 that is further characterized as exhibiting an X-Ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 9 . 
Kristalni oblik prema bilo kojem od zahtjeva 1-3, naznačen time da navedeni kristalni oblik ima spektar difrakcije X-zraka praha (XRPD) isti kao što je prikazan na Slici 2.
In one embodiment, the amino acid residue is an asparagine residue. In another embodiment, said G-CSF peptide comprises a structure according to the formula 
Peptid za uporabu prema zahtjevu 2, gdje je taj aminokiselinski ostatak treonin na položaju 134 u SEQ.
The liquefied gas treatment system according to claim 2, wherein the compressor includes a plurality of compression cylinders. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što je kompresor (13,13a,13b) višestadijski kompresor koji sadrži kompresijskih elemenata (14,14a,14b).
The liquefied gas treatment system according to claim 7, wherein the BOG supplied to the sub engine is BOG that is compressed while passing through all or part of the plurality of compression cylinders included in the compressor. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 4, naznačen time što otpareni plin poslan u izmjenjivač topline (21) je otpareni plin komprimiran prilikom prolaska kroz sve ili dio kompresijskih elemenata koje sadrži kompresor (13,13a,13b).
The lead composition of clause 26 wherein the alkane sulfonic acid is methane sulfonic acid and wherein the chelator is EDTA (ethylene diamine tetraacetic acid). 
Supstanca olova sukladno patentnom zahtjevu 14 pri čemu je alkan sulfonska kiselina metan sulfonska kiselina i pri čemu je taj kelator etilen diamin tetraoctena kiselina (EDTA).
NOR4, wherein, when X is b) or c), R4 is a hydrogen atom, a phenyl group optionally having substituent(s), a heterocyclic group optionally having substituent(s), or a C1 to C6 alkyl group optionally having substituent(s); 
NOR4, gdje, kada X je b) ili c), R4 je atom vodika, fenil grupa koja po izboru ima supstituent(e), heterociklična grupa koja po izboru ima supstituent(e), ili C1 do C6 alkil grupa koja po izboru ima supstituent(e);
The method of clause 21, wherein the larger particles are circulating tumor cells (CTCs) and the smaller particles are blood cells. 
(CTC) a manje čestice su stanice krvi. Postupak prema bilo kom od patentnih zahtjeva 12 do 14, pri čemu veće čestice jesu stanice fetusa a manje čestice jesu stanice krvi.
System according to claims 7 or 8, wherein the further mobile communication technology is a technology according one of the IEEE-802.11-family of mobile communication standards. 
Sustav prema zahtjevima 7 ili 8, pri čemu je druga mobilna komunikacijska tehnologija tehnologija prema jednom iz IFEE-802.11-seta standarda za mobilne komunikacije.
The antibody polypeptide of any of embodiments 1-16, wherein the antibody polypeptide is a fusion polypeptide comprising the first variable domain and an Fc domain. 
Polipeptid antitijela prema bilo kojem od patentnih zahtjeva 1-3, gdje polipeptid antitijela je fuzioni polipeptid koji sadrži prvi varijabilni domen i Fc domen.
The negative electrode preferably consists of lithium metal, which may be in the form of a lithium sheet or a foil, or a combination of a compressed lithium sheet or foil and dendrites, or preferably lithium dendrites as such. 
Litijski akumulator prema zahtjevu 11 u kojem je metal litija u obliku lista ili folije litija, ili kombinacije prešanog lista litija ili folije i litij dendrita ili u obliku litijevih dendrita.
Further anti-solvent for the salt, e.g. 
Nadalje anti otapalo za sol, npr.
The temperature induced transformation of packages of plastic material containing a number of roofing cement-asbestos slates of 50 to 70, or other asbestos containing wastes such as friable asbestos with the process described at point 1) 
zaprimanje i privremeno skladištenje paketa otpada koji sadrži azbest, hermetički umotanih u plastični materijal, koji sadrže od 50 do 70 krovnih ploča od azbestnog cementa ili drugog otpada koji sadrži azbest,
After the glass blanks are formed, the blank mold 16 is opened and the glass blanks disposed on the neck rings 172 are ready for transfer to the blow mold side of the machine. 
Nakon što je oblikovana gruba talina, grubi kalup (16) se otvara, te se talina može premjestiti na puhačku stranu stroja pomoću izdanaka kalupa (172).
energizing said motor assembly (22, 24) for rotating said mixing element (60) in said second direction (B), and 
pogonjenja navedenog motorskog sklopa (22, 24) radi vrtnje navedenog elementa za miješanje (60) u navedenom drugom smjeru (B) i -
a high bind carbon plate; a porous carbon surface; a carbon surface, glass surface, silica surface, metal surface, a polymeric material, a surface containing a metallic or chemical coating, a membrane, a bead, a porous polymer matrix, or substrates comprising cellulosic fibers, or any combination thereof; 
Postupak prema zahtjevu 1, naznačen time što supstrat sadrži površinu ugljika, staklenu površinu, površinu silicija, metalnu površinu, polimerni materijal, površinu koja sadrži metalnu ili kemijsku prevlaku, membranu, zrnca, poroznu polimernu matricu, ili supstrate koji sadrže celulozna vlakna, ili bilo koju njihovu kombinaciju.
The method according to claim 9, wherein the benzyl is removed using zinc and acetyl chloride. 
Postupak prema zahtjevu 10, gdje Pr je benzil i uklanja se pomoću cinka i acetil klorida.
are as defined for formula (I) 
1 Spoj formule (1),
represents a methyl, ethyl or trifluoromethyl group; R10, R11 represent, independently from each other, a group selected from hydrogen, C1-C2-alkyl-; and the enantiomers, diastereomers, salts, solvates or salts of solvates thereof. 
R* predstavlja skupinu metil, etil ili trifluormetil; R'", R" predstavljaju, međusobno neovisno, skupinu koja je odabrana od vodika, C;-C>-alkila-; i njihovi enantiomeri, diastereomeri, soli, solvati ili soli solvata.
The pharmaceutical composition for use according to any one of claims 6-13, wherein said fungal infection is an infection of Candida albicans, C. parapsilosis, C. glabrata, C. guilliermondii, C. krusei, C. tropicalis, C. lusitaniae, Aspergillus fumigatus, A. flavus, A. terreus, A. niger, A. candidus, A. clavatus, or A. ochraceus. 
Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 6-13, naznačen time da navedena gljivična infekcija je infekcija sa Candida albicans, Ć. parapsilosis, C. glabrata, C. guilliermondii, C. krusei, Ć. tropicalis, C. lusitaniae, Aspergillus fumigatus, A. flavus, A. terreus, A. niger, A. candidus, A. clavatus, ili A. ochraceus.
Comparison of Serum Cholesterol Levels in Rats Treated with Rapamycin and 42-O. (D-Fructosylcarbonyl)rapamycin 42-O-(D-fructosylcarbonyl)rapamycin and rapamaycin were tested head-to-head in Sprague-Dawley rats for changes in cholesterol level. 
Usporedba serumskih razina kolesterola u štakora tretiranih rapamicinom i 42-0-(D-fruktozilkarbonil)rapamicinom 42-0-(D-fruktozilkarbonil)rapamicin i rapamicin testirani su u Sprague-Dawley štakora radi praćenja promjena u razinama kolesterola.
aromatic or may specifically be: R13 H, alkyl group such as a methyl or ethyl group, olefinic or 
H, alkil skupina kao što je metil ili etil skupina, olefinska ili aromatska skupina ili može posebno biti: zombi
The incineration grate according to claim 1, wherein the pocket, the at least one pin, or a combination thereof is arranged adjacent to or bordering a die removal plane or the connecting surfaces, or is intersected by the die removal plane or the connecting surfaces. 
Rešetka za spaljivanje prema jednom ili više prethodnih patentnih zahtjeva, naznačena time da su džep (6) i/ili trn (5) raspoređeni susjedno ili granično sa ravninom za uklanjanje kalupa (18) ili povezujućom površinom (3), ili ih ona presijeca.
ring A is independently selected from 6-membered aryl and 5- to 6-membered heterocyclyl, wherein said aryl and heterocyclyl are optionally substituted with, where valence allows, one or more R4; 
Spoj formule (I): a-V1a-C(=O)-P1a-W1a-P1b-C(=O)-V1b-E1b (I) gdje a je i W1a je po izboru supstituiran sa jednom ili više grupa koje su nezavisno odabrane od halo, alkil, haloalkil, ili cijano;
A non-limiting list of permeation enhancing agents includes polyethylene glycols, surfactants, and the like. 
Bezgranični popis sredstava za poboljšavanje prodiranja uključuje polietilen glikole, surfaktante, i slično.
Use or HfO2 nanoparticles or HfO2 nanoparticles' aggregates for use according to claim 6, wherein the ionizing radiations are of about 2 KeV to 1500 KeV. 
Uporaba ili nanočestice HfO, 1li agregati nanočestica HfO, za uporabu prema zahtjevu 6, gdje su ionizirajuća zračenja od oko 2 KeV do 1500 Kev.
In view of the above, it is apparent that the appropriate selection of a linker group providing suitable orientation, entropy and physico-chemical properties is well within the skill of the art. 
U svjetlu gore navedenog, očito je da odgovarajući izbor vezničke grupe, uz uvjet da omogućuje prikladnu orijentaciju, entropiju i fizikalno-kemijska svojstva, ulazi u znanje struke.
A method of treating a cellular proliferation disease in a subject comprising administering to the subject a therapeutically effective amount of the compound according to claim 1 . 
Spoj koji se, sukladno patentnom zahtjevu 1, koristi kao metoda liječenja bolesti stanične poliferacije kod pojedinca.
the amino portion of such substituents optionally is substituted with a substituent independently selected from the group consisting of carbocyclylalkyl, heterocyclylalkyl, alkylcarbonyloxy, aminocarbonylalkyl, alkyl, alkylcarbonyl, alkyloxycarbonyl, alkyloxyalkyloxycarbonyl, alkylcarbonyloxyalkyl, and alkylsulfonyl, wherein: 
(a) amino dio takvog supstituenta je po izboru supstituiran supstituentom koji je odabran iz skupine koja sadrži karbociklilalkil, heterociklilalkil, alkilkarboniloksi, aminokarbonilalkil, alkil, alkilkarbonil, alkiloksikarbonil, alkiloksialkiloksikarbonil, alkilkarboniloksialkil i alkilsulfonil, gdje:
the sum total of the 5' and the 3' homology arms of the LTVEC is from about 10 kb to about 150 kb; or 
(b) zbroj ukupnih 5' i 3' homolognih dijelova LTVEC-a je od oko 16 kb do oko 150 kb.
The compound for use according to claim 22, wherein the disease is psoriasis or sarcoidosis. 
Spoj za uporabu prema zahtjevu 21, naznačen time da je stanje psorijaza ili sarkoidoza.
X is a carbon atom; and 
R" je atom vodika.
For the orthogonal arrangement structure which is illustrated in FIG. 2 c, nothing is changed in the production process according to the invention, and these considerations can be applied correspondingly. 
Za okomitu strukturu naprave, koja je prikazana na slici 2c, ništa se ne mijenja u proizvodnom postupku prema izumu, i ta se razmatranja mogu odgovarajuće primijeniti.
A fifth specific embodiment of the invention is represented in table 14. 
Peta specifična varijanta prikazana je u Tablici 14.
In transplantation, mTOR inhibitors are typically used in combination with calcineurin inhibitors. 
U transplantaciji, mTOR inhibitori tipično se koriste u kombinaciji s inhibitorima kalcineurina.
Pharmaceutical for use according to claim 3, characterized in that it is an inhalable aerosol with or without propellant, or an inhalable dry powder or an inhalable suspension or an inhalable solution. 
6. Farmaceutski proizvod sukladno patentnom zahtjevu 5, naznačen time, da je taj proizvod suhi prašak za inhaliranje, aerosol za inhaliranje sa ili bez potisnog plina ili inhalacijska suspenzija ili otopina.
and R6′, together with the N-atom to which they are attached, form a (C5-C10)heterocyclyl group. 
Rs i Rg', zajedno s N-atomom na kojeg su vezani, tvore (Cs-C,o)heterociklilnu skupinu.
In certain embodiments, the at least one heat exchanger comprises an accept heat exchanger arranged between the chamber or surface and the fluid conduit; the at least one forced convection unit is arranged to enhance transfer of heat from the chamber or surface to the accept heat exchanger; the heat transport system comprises at least one thermoelectric heat pump arranged to receive heat from the accept heat exchanger; and the method further comprises selectively controlling the at least one forced convection unit responsive to temperature of the chamber or surface. 
Postupak prema bilo kojem od zahtjeva 11 ili 12, naznačen time, da: najmanje jedan izmjenjivač topline obuhvaća prihvatni izmjenjivač topline smješten između komore ili površine 1 fluidnog cjevovoda; najmanje jedan uređaj za prisilno toplinsko strujanje, raspoređen je za pojačanje prijenosa topline iz komore ili s površine do prihvatnog izmjenjivača topline; sustav za prijenos topline obuhvaća najmanje jednu termoelektričnu toplinsku pumpu namještenu za primanje topline iz prihvatnog izmjenjivača topline; i postupak nadalje obuhvaća selektivno upravljanje najmanje jednim uređajem za prisilno toplinsko strujanje, koje se vrši u skladu s reakcijom na temperaturno stanje u komori ili na površini.
The method according to claim 3, characterised in that the heat exchanging component is a superheater and the high pressure bypass control valve (26) is downstream of the superheater. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što je komponenta za izmjenu topline pregrijač, a ventil za kontrolu visokotlačne obilaznice (26) se nalazi nizvodno od pregrijača.
In brief, this invention is generally directed to gonadotropin-releasing hormone (GnRH) receptor antagonists, as well as to methods for their preparation and use, and to pharmaceutical compositions containing the same. 
Ukratko, ovaj izum općenito se odnosi na antagoniste receptora gonadotropin-oslobađajućeg hormona (GnRH), kao 1 na postupke njihovog dobivanja i upotrebe, te na farmaceutske pripravke koji sadrže iste.
In our experiments, we applied the Bennet-Xie model (G.J. Bennett, Y.-K. Xie, Pain 33: 87-107; 1988) to test the effect of the combination against neuropathic pain. 
Proučavanje analgezije Model alodinije na štakorima U našim pokusima, za ispitivanje učinka kombinacije protiv neuropatske boli primijenili smo model Bennet-Xie (G.J.
In other embodiments, the poly(lactic) acid-poly(ethylene)glycol copolymer has a number average molecular weight of about 16kDa poly(lactic acid) and a number average molecular weight of about 5kDa poly(ethylene)glycol. 
Terapeutska nanočestica prema zahtjevu 2, naznačena time da kopolimer poli(ćmliječna) kiselina-poli(etilen)glikol ima iznos prosječne molekularne težine od 16kDa poli(mliječna kiselina) i iznos prosječne molekularne težine od 5kDa poli(etilen)glikola.
represents an unsubstituted 4-pyridine ring or 4-pyrimidine ring; and/or 
R1 predstavlja nesupstituiran 4-piridinski prsten ili 4-pirimidinski prsten; i/ili
The elastomer material of the present invention provides the advantage that under irradiation from a focused 980 nm laser of power less than 20 W, typically 4-10 W, e.g. ca. 8 W the thermoplastic elastomer material easily fuses e.g. after ca. 0.5-2 seconds, e.g. 1 second maximum irradiation, and sets on cooling without emission of significant quantities of contaminating smoke. 
Elastomerni materijal koji se koristi u predmetnom izumu osigurava prednost da se pod djelovanjem zračenja 980 nm fokusiranog lasera snage manje od 20 W, tipično 4 - 10 W, na primjer, oko 8 W, termoplastični elastomerni materijal lako lijepi, na primjer nakon trajanja zračenja od oko 0.5 - 2 sekunde, na primjer, maksimalno 1 sekunde, i zatim se nastavlja hlađenje bez emitiranja značajnih količina kontaminiranog dima.
The pharmaceutical composition as claimed in claim 5, for the treatment and/or prevention of clinical conditions such as withdrawal from drug abuse syndrome, stroke, head trauma, mild cognitive impairment, neurodegenerative disorders, gastrointestinal and obesity. 
Farmaceutski pripravak prema zahtjevu 5, naznačen time da je za liječenje i/ili sprječavanje kliničkih stanja kao što su odvikavanje od sindroma zlouporabe droga, udar, ozljeda glave, blago kognitivno oštećenje, neurodegenerativni poremećaji, gastrointestinalni poremećaji i pretilost.
A method of preparation of the compound according to daims 1-8, characterized in that trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz [2,3:6,7] oxepino [4,5-c] pyrrole (Z)-2-butenedioate is crystallized from an ethanol/water mixture. 
Postupak za dobivanje spoja prema Zahtjevima 1-8, naznačen time, da je trans-5-kloro-2,3,3a, 12b-tetrahidro-2-metil-1H-dibenz [2,3:6,7] oksepino [4,5-c] pirol (Z)-2-butendioat kristaliziran iz smjese etanol/voda.
The immunogenic compound according to claim 4, wherein the said linker moiety consists of succimidyl 4-[p -maleimidophenyl]butyrate (SMPB) or sulfo-SMPB. 
Imunogeni spoj prema zahtjevu 5, naznačen time da navedena skupina premosnice sadrži sukcimidil 4-[p-maleimidofenil]butirat (SMPB) i sulfo-SMPB.
Example 8 Preparation of Coated Micropellets 
Primjer 8: Izrada obloženih mikropeleta
about 0.5% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 75.5% metformin hydrochloride; about 6% hydroxypropyl cellulose; 12.5% microcrystalline cellulose; 5% sodium starch glycolate; and 0.6% magnesium stearate; 
(F) oko 0.5% dapagliflozina ili dapagliflozin (S) propilen glikol hidrata; oko 75.5% metformin hidroklorida; oko 6% hidroksipropil celuloze; 12.5% mikrokristalne celuloze; 5% natrijevog škrob glikolata; i 0.6% magnezijevog stearata;
a conveyor belt device (10) having a supporting belt (11), 
uređaj s pokretnom vrpcom (10), koji ima nosivu vrpcu (11),
a wrapper surrounding the column of the smokable tobacco, the wrapper comprising cellulosic fibers and containing a single filler, the single filler having a median particle size of greater than about 3.2 microns, characterized in that the single filler is in the wrapper in an amount less than 20% by weight, wherein the wrapper has a Burn Mode Index (BMI) of less than 3 cm-1; and 
omotač koji opkoljava stupac duhana za pušenje, pri čemu omotač: sadrži celulozna vlakna i punilo, a punilo ima srednju veličinu čestica veću od oko 3,2 mikrona; i ima propustljivost od oko 15 Coresta do oko 80 Coresta; i
The extended release dosage form of any one of claims 1 to 28, which is in the form of a tablet formed by direct compression of the composition and cured by at least subjecting said tablet to a temperature of at least about 60 °C or at least about 62 °C for a time period of at least about 1 minute, preferably at least about 5 minutes or at least about 15 minutes. 
Oblik davanja s produljenim otpuštanjem prema bilo kojem zahtjevu od 1 do 14, naznačen time da je u obliku tablete formirane pomoću direktne kompresije sastava i stvrdnute najmanje podvrgavanjem navedene tableta temperaturi od barem oko 60°C ili barem oko 62°C u vremenskom periodu od barem oko 1 minute, poželjno barem oko 5 minuta ili barem oko 15 minuta.
The method according to claim 10, further comprising testing said synthesized MHC ligand peptide for immunogenicity. 
Metoda prema zahtjevu 9, gdje je prezentacijski rezultat prilagođen za višekratno testiranje uporabom lažne stope pronalaženja.
A method according to claim 1, 2 or 3, wherein the subject is a human individual which has been vaccinated against rabies. 
Postupak prema zahtjevu 1, 2 ili 3, naznačen time da je subjekt čovjek pojedinac koji je bio cijepljen protiv bjesnoće.
In another particular embodiment, the eye drop vehicle in the invention is an isotonic aqueous solution, such as the isotonic solution of sodium chloride or boric acid, or is a poly(vinyl alcohol) aqueous solution or mixtures thereof. 
Topikalna očna kompozicija za primjenu u skladu sa zahtjevom 2, naznačena time što je nosač otopine kapi za oči neka izotonična vodena topina, neka poli(vinil-alkoholna) vodena otopina ili njihova smjesa.
A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition of claim 17, further comprising an active ingredient selected from the group consisting of a) an antagonist of integrin a5B1, b) a cytotoxic/antiproliferative agent, c) an inhibitor of epidermal-derived, fibroblast-derived, or platelet-derived growth factor, d) an inhibitor of VEGF, e) an inhibitor of Flk-1/KDR, Flt-1, Tck/Tie-2, or Tic-1, and f) an inhibitor of phosphoinositide 3-kinase, and a mixture thereof. 
Farmaceutski preparat, koji sadrži spoj prema bilo kojem od prethodnih patentnih zahtjeva ili njegovu farmaceutski prihvatljivu sol ili solvat, i farmaceutski prihvatljiv nosač ili ekscipijens, naznačen time, da farmaceutski preparat opcijski dalje sadrži aktivni sastojak odabran iz skupine koja se sastoji od a) antagonista integrina o5B1, b) citotoksičnog / antiproliferativnog agensa, c) inhibitora faktora rasta izvedenog iz epiderma, izvedenog iz fibroblasta, ili izvedenog iz trombocita, d) inhibitora VEGE, e) inhibitora FIk-1/KDR, FIt-1, Tck/Tie-2 ili Tic-1,1 1) inhibitora fosfoinozitid 3-kinaze i njihove mješavine.
The reaction mixture was filtered and evaporated. 
Reakcijska smjesa se filtrira i upari.
Typically the product is for simultaneous, separate or sequential use in the treatment of a respiratory disease which responds to M3 antagonism in a human or animal patient. 
Obično je navedeni proizvod namijenjen za istovremenu, odvojenu ili sekvencijalnu uporabu u liječenju respiratornih bolesti koje odgovaraju na M3 antagonizam u bolesnih ljudi ili životinja.
reacting a cobalt compound with a carboxylic acid functional polymer having a mean molecular weight of more than 2000; 
- reakcija spoja kobalta, poželjno kobaltova hidroksida, s funkcionalnim polimerom karboksilne kiseline koji ima prosječnu molekulsku masu veću od 2000;
The method of claim 1 comprising the further step of preparing a unitary dosage form comprising the dry granules. 
Postupak prema patentnom zahtjevu 1, naznačen time što sadrži dodatni korak pripreme oblika jedinične doze koji sadrži suhe granule.